Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coumarin-caged CPA
- Development stage
- Preclinical
- Lead developer
- Ghent University
- Modality
- Small Molecules
- Administration
- Intracerebroventricular
01
Overview
Coumarin-caged CPA (pcCPA) is a photopharmacological tool and potential therapeutic candidate designed for the spatially selective modulation of neural excitability. It consists of the potent adenosine A1 receptor (A1R) agonist, N6-cyclopentyladenosine (CPA), chemically "caged" with a coumarin moiety that renders the molecule inactive. Upon exposure to specific wavelengths of light (illumination), the coumarin cage is cleaved, releasing active CPA to activate A1 receptors. This approach aims to reduce hyperexcitability in the dentate gyrus, a key area involved in mesial temporal lobe epilepsy (MTLE), while minimizing systemic side effects associated with global A1R activation. Research indicates its feasibility in closed-loop systems to maintain neurotransmission at target levels in epilepsy models.
- Other names
- photocaged CPAcoumarin-caged N6-cyclopentyladenosine
02
Targets
ADORA3 (Adenosine A3 receptor)ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)ADORA2B (Adenosine A2B receptor)
Beyond the preview
Go deeper on coumarin-caged CPA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coumarin-caged CPA.